Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Unicycive Therapeutics, Inc. (UNCY)

Unicycive faces securities class action over statements on its new drug application

Negative Impact 3 of 5 legal/regulatory Written later

Unicycive Therapeutics disclosed that a securities class action was filed on September 3, 2026, in the U.S. District Court for the Northern District of California against the company and certain officers. The suit alleges violations of federal securities laws tied to public statements about the company's new drug application for oxylanthanum carbonate phosphate binder. The company says the claims are meritless and plans to defend the lawsuit vigorously, but the filing does not state any financial impact.

Key points

  • Class action filed September 3, 2026, in U.S. District Court for the Northern District of California
  • Suit names the company and certain officers and alleges federal securities law violations
  • Allegations relate to public statements about the new drug application for oxylanthanum carbonate phosphate binder for hyperphosphatemia in dialysis patients with chronic kidney disease
  • Company says the claims are meritless and intends to vigorously defend

The filing

CompanyUnicycive Therapeutics, Inc. (UNCY)
Form8-K, current report
Filed with the SECSep 28, 2026, 4:31 PM ET
Accession number0001213900-26-104076

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.